Back to top

CalciMedica, FDA alignment de-risks regulatory path, says H.C. Wainwright

FDA alignment on CalciMedica’s (CALC) acute pancreatitis program for Auxora de-risks the regulatory path, validating Phase 2b endpoint selection an...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

CalciMedica Inc. (CALC)